Connor, Clark & Lunn Investment Management (CC&L)
RLMD icon

Connor, Clark & Lunn Investment Management (CC&L)’s Relmada Therapeutics RLMD Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,426
Closed -$123K – 1646
2024
Q1 		$123K Sell
26,426
-34,735
-57% -$167K ﹤0.01% 1452
2023
Q4 		$253K Sell
61,161
-25,992
-30% -$77K ﹤0.01% 1213
2023
Q3 		$261K Sell
87,153
-17,362
-17% -$51.6K ﹤0.01% 1179
2023
Q2 		$257K Sell
104,515
-5,444
-5% -$15.1K ﹤0.01% 1144
2023
Q1 		$249K Sell
109,959
-8,692
-7% -$30K ﹤0.01% 1048
2022
Q4 		$414K Buy
118,651
+84,315
+246% +$740K ﹤0.01% 916
2022
Q3 		$1.27M Buy
+34,336
New +$951K 0.01% 600

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RLMD Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 26,426 shares — an estimated $123K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RLMD in Q3 2022 and held it in 7 quarters. The position peaked at $1.27M in Q3 2022. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,426 Relmada Therapeutics shares in Q2 2024, an estimated $123K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Relmada Therapeutics in Q3 2022 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Relmada Therapeutics position peaked at $1.27M in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.